Editas Medicine Stock Forecast, Price & News

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 4 sell ratings, 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Editas Medicine stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View analyst ratings for Editas Medicine or view top-rated stocks.

Wall Street analysts have given Editas Medicine a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Editas Medicine wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Editas Medicine is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Editas Medicine.

Editas Medicine, Inc. (NASDAQ:EDIT) posted its quarterly earnings results on Wednesday, August, 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.04. The firm earned $0.38 million during the quarter, compared to analyst estimates of $6.78 million. Editas Medicine had a negative trailing twelve-month return on equity of 31.96% and a negative net margin of 205.41%. Editas Medicine's revenue for the quarter was down 96.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.43) earnings per share.
View Editas Medicine's earnings history.

Editas Medicine's stock was trading at $20.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EDIT shares have increased by 211.8% and is now trading at $63.20.
View which stocks have been most impacted by COVID-19.

15 brokers have issued twelve-month target prices for Editas Medicine's stock. Their forecasts range from $14.00 to $86.00. On average, they expect Editas Medicine's share price to reach $56.53 in the next twelve months. This suggests that the stock has a possible downside of 10.5%.
View analysts' price targets for Editas Medicine or view top-rated stocks among Wall Street analysts.

Some companies that are related to Editas Medicine include argenx (ARGX), Repligen (RGEN), QIAGEN (QGEN), CRISPR Therapeutics (CRSP), Neurocrine Biosciences (NBIX), Acceleron Pharma (XLRN), Vir Biotechnology (VIR), Beam Therapeutics (BEAM), Fate Therapeutics (FATE), Exelixis (EXEL), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Halozyme Therapeutics (HALO), Adaptive Biotechnologies (ADPT) and Adagio Therapeutics (ADGI).
View all of EDIT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Square (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

(EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Editas Medicine's stock is owned by many different institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (10.59%), Vanguard Group Inc. (9.50%), BlackRock Inc. (8.23%), Sumitomo Mitsui Trust Holdings Inc. (7.19%), Nikko Asset Management Americas Inc. (7.18%) and State Street Corp (3.71%). Company insiders that own Editas Medicine stock include Charles Albright, Cynthia Collins and Michelle Robertson.
View institutional ownership trends for Editas Medicine.

EDIT stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Federated Hermes Inc., Renaissance Technologies LLC, Morgan Stanley, Morgan Stanley, BlackRock Inc., Segall Bryant & Hamill LLC, and Group One Trading L.P.. Company insiders that have sold Editas Medicine company stock in the last year include Charles Albright, and Michelle Robertson.
View insider buying and selling activity for Editas Medicine or view top insider-selling stocks.

EDIT stock was bought by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Dimensional Fund Advisors LP, Discovery Value Fund, State Street Corp, Parallax Volatility Advisers L.P., and JPMorgan Chase & Co..
View insider buying and selling activity for Editas Medicine or or view top insider-buying stocks.

Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EDIT stock can currently be purchased for approximately $63.20.

Editas Medicine has a market capitalization of $4.31 billion and generates $90.73 million in revenue each year. The company earns $-115,980,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis.

Editas Medicine employs 235 workers across the globe.

The official website for Editas Medicine is www.editasmedicine.com.

Editas Medicine is headquartered at 11 Hurley Street, Cambridge MA, 02141.

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at (617) 401-9000 or via email at [email protected]